PRESERVING PATIENT ACCESS TO COMPOUNDED MEDICATIONS H.R. 2871
|
|
- Spencer Shelton
- 5 years ago
- Views:
Transcription
1 PRESERVING PATIENT ACCESS TO COMPOUNDED MEDICATIONS H.R BACKGROUND: Compounded medications are used to treat patients with unique medical conditions that make them resistant to standard medications. For example, using active ingredients without preservatives or allergenic substances, or putting an active ingredient in substances to be used topically or intravenously instead of orally for patients with digestive issues. Many nutritional and herbal remedies are also only available through compounding pharmacies, because large pharmaceutical manufacturers do not make small batches of these products. These compounded products are used to treat a variety of conditions, including digestive disorders, chronic viral infections, anemia and vitamin deficiencies; migraine, colitis, asthma, hepatitis, diabetes, Parkinson s, chronic fatigue and other autoimmune disorders, or supportive therapies to mitigate side-effects of chemotherapy. They are essential for millions. Historically, naturopathic doctors, along with Dermatologists, Opthamologists and many other provider types, maintain a supply of compounded medications to administer to a patient in the physician s office for the immediate treatment of a problem, a practice governed by state law and referred to as office-use. This supply is obtained by the physician, without requiring an advance prescription for each individual patient. The Drug Quality & Security Act (DQSA, P.L ) was enacted in response to a meningitis outbreak from contaminated sterile drugs compounded that tragically resulted in dozens of deaths. The DQSA gives the FDA new oversight over some compounding facilities to address these safety concerns. Neither office use or the rejection of dietary supplement monographs have anything to do with the meningitis outbreak, and in passing the DQSA, Congress made clear statements noting the importance of maintaining patient access to office-use drugs and ensuring that compounding regulations should not interfere with the practice of medicine. Since passage of the DQSA, the FDA has interpreted certain provisions of the law in a manner inconsistent with legislative intent to expand its oversight over physicians and compounding pharmacies, and the medications compounded by these pharmacies. ISSUE #1: OFFICE-USE FDA has issued non-binding guidance for industry (GFI) documents that do not have the force of law or administrative rule to restrict office-use of compounded medications. FDA guidance now requires that physicians may not use compounded medications for office-use to treat patients in real time. Instead, a physician must write a patient-specific prescription.
2 What formerly could be treated in the same visit now requires: 1) a trip to the physician office for evaluation and diagnosis, 2) a trip to the pharmacy to obtain the prescription, and 3) a follow-up visit to the physician office to administer the treatment. This causes a number of problems: Delays in patient care Increased patient cost of care through additional co-pays Increased risk of patients not adhering to a treatment protocol Increased risk to patients if the prescriptions - many of which require refrigeration or degrade easily - are not handled or stored safely by the patient Decreased supply of drugs, some pharmacies have stopped providing some compounded drugs Increased cost of prescriptions since each prescription is made specific for the patient instead of available in bulk through the physician ISSUE #2: DRUG INGREDIENTS FDA has also started a process to take long-used safe ingredients that are compounded for patients off the market. They have required that any substance that does not have a Drug Monograph in the US Pharmacopeia or National Formulary must be nominated for approval to compound. Of 453 ingredients that were nominated for the FDA s Pharmacy Compounding Advisory Committee (PCAC) to review, they have refused to review 390 ingredients. PCAC has further rejected 71% of the 49 ingredients that they have reviewed to date, despite a long history of safe use and patient need. Yet many of these ingredients have U.S. Pharmacopeia Dietary Supplement monographs, which Congress intended to also be available for compounding but which FDA has refused to accept. If these monographs are not accepted, this will have the effect of restricting patient access to over 400 compounded drugs currently being used by hundreds of thousands of patients. LEGISLATIVE ASK: Representatives Morgan Griffith (R-VA) and Henry Cuellar (D-TX) have introduced the Preserving Patient Access to Compounded Medications Act (H.R. 2871), which would clarify congressional intent regarding key provisions of the Food, Drug and Cosmetic Act (FDCA) as amended by the DQSA. H.R would allow traditional compounding pharmacies to distribute compounded drugs for office-use without a patient-specific prescription in all states that allow office-use compounding, and would clarify acceptance of ingredients for compounding with dietary supplement as well as drug monographs. HOUSE: Cosponsor the Preserving Patient Access to Compounded Medications Act (H.R. 2871) introduced by Representatives Morgan Griffith (R-VA) and Henry Cuellar (D-TX) Request a hearing for H.R SENATE: Sponsor or cosponsor a Senate companion bill, and support H.R. 2871
3 SECTION-BY-SECTION SUMMARY OF H.R. 2871: SECTION 1. SHORT TITLE. The bill is to be titled the Preserving Patient Access to Compounded Medications Act of SECTION 2. OFFICE-USE COMPOUNDING WHEN AUTHORIZED BY STATE LAW. This section of the bill amends Section 503A of the Food, Drug and Cosmetic Act to state that the compounding of medications by a licensed pharmacist or licensed physician for officeadministration to a patient in an office or clinical setting is permissible under 503A when done in accordance with State law. The compounding must be done pursuant to a valid prescription order or drug order and distributed or dispensed to a licensed prescriber in accordance with State law, for administration to a patient in an office or clinical setting. SECTION 3. UNITED STATES PHARMACOPOEIA OR NATIONAL FORMULARY REQUREMENT. This section of the bill clarifies that it is permissible under Section 503A(b)(1)(A) of the Food, Drug and Cosmetic Act for a licensed pharmacist or a licensed physician to compound a drug product using bulk drug substances that comply with the monograph standards of the United States Pharmacopoeia or National Formulary, including a drug substance or dietary supplement monograph. The section does not change the current requirements of 503A(b)(1)(A) that if a monograph does not exist, the drug substance may only be used for compounding if it is a component of an FDA approved drug or if it appears on a positive list developed by the Secretary. SECTION 4. DEFINITIONS. This section of the bill adds two new definitions to Subsection (e) of section 503A of the Food, Drug and Cosmetic Act. The section defines Distribute or Distribution to clarify that those terms do not include the act of dispensing a compounded drug product in accordance with Section 503A. Section 4 of the bill also defines Dispense to mean, for a drug product compounded in accordance with Section 503A, the act of the drug product leaving the facility in which it was compounded for delivery to a patient, patient s agent, or health care facility (including a hospital, physician s office, or other health care setting) pursuant to a valid prescription order for an identified patient. SECTION 5. APPLICABILITY OF RECORDS EXEMPTION FOR COMPOUNDING PHARMACIES. This section of the bill clarifies that when inspected by FDA, the records exemption provided in existing Section 704(a)(2)(A) of the Federal Food, Drug and Cosmetic Act to pharmacies which maintain establishments in conformance with local laws regulating the practice of pharmacy and medicine, apply to compounding pharmacies that are also in compliance with the provisions of 503A of the Food, Drug and Cosmetic Act as amended by this bill. This section of the bill also
4 clarifies that the exemption from FDA manufacturer registration requirements provided in existing Section 510(g)(1) of the Food, Drug and Cosmetic Act for pharmacies which maintain establishments in conformance with local laws regulating the practice of pharmacy and medicine, apply to compounding pharmacies that are also in compliance with the provisions of 503A of the Food, Drug and Cosmetic Act as amended by this bill. SECTION 6. REGULATIONS. This section of the bill requires the Secretary of Health and Human Services to, within 90 days of enactment of this Act, promulgate rules on the record to carry out the amendments to the law made by the bill. This section will also require the Secretary to promulgate rules on the record to carry out other provisions of Section 503A of the Food, Drug and Cosmetic Act not amended by the bill (the provisions of 503A in existing law).
5 NATUROPATHIC DOCTORS AND THE COMPREHENSIVE ADDICTION AND RECOVERY ACT 2.0 (S and H.R. 5311) BACKGROUND: Chronic and acute pain is one of the most common complaints seen in all medical practices, including those of naturopathic doctors. Ineffective pain control and relief has led to billions of dollars in lost productivity, a galloping increase in the prescription use of opioid pain relievers, and unprecedented deaths from addiction and drug abuse. Licensed Naturopathic Doctors use a variety of safe and effective therapies to relieve pain, mostly focused on non-pharmacological approaches but in some states also using Medication-Assisted Treatment (MAT) for recovery options. Studies show that naturopathic treatments compared to conventional medical treatments show similar or greater pain relief, with an increase of quality of life, diminished costs, fewer missed work days, and the best, no addiction to prescription medications. Savings of nearly $1,000 per patient with low back pain using naturopathic therapies, with missed work due to illness diminished by 6.7 days, leading to return on investment 1 of 7.9 percent. 60 percent pain reduction in patients of naturopathic doctors in a complementary and 2 alternative medicine pain clinic. 54 percent reduction in pain, better outcomes and diminished disability in a randomized controlled trial (RCT) study on rotator cuff tendinitis in postal workers from therapies 3 administered by licensed naturopathic doctors. PROBLEM: ENSURING PATIENT ACCESS TO MEDICATION-ASSISTED TREATMENT Only one in 10 people in the U.S. with an addiction receive treatment. According to the Pew Charitable Trusts, that s in large part because of a shortage of trained medical providers, 4 especially ones who can prescribe buprenorphine. 1 Herman PM, Szczurko O, Cooley K, Mills EJ. Cost-effectiveness of naturopathic care for chronic low back pain. (2008) Altern Ther Health Med Mar-Apr 14 (2): Secor ER, Markow MJ, Mackenzie J, Thrall RS. Implementation of outcome measures in a complementary and alternative medicine clinic: evidence of decreased pain and improved quality of life. (2004) J Altern Complement Med 10: Szczurko O, Cooley K, Mills EJ, Zhou Q, Perri D. Naturopathic treatment of rotator cuff tendinitis among Canadian postal workers: a randomized controlled trial. (2009) Arthritis Rheum 61:
6 Section 303 of CARA was previously amended to allow physician assistants and nurse practitioners to prescribe buprenorphine under the direction of a qualified physician, and is set to sunset in S makes a permanent addition of nurse practitioners and physicians assistants as Qualifying Other Practitioners who can prescribe buprenorphine. H.R would add a variety of other nurses as well as physicians assistants to the list of Qualifying Other Practitioners. Licensed naturopathic doctors receive more training and education than both physician assistants and nurse practitioners, and several states authorize naturopathic doctors to prescribe the DEA schedules necessary for Medication-Assisted Treatment like buprenorphine. Many naturopathic doctors treat patients with addiction involving opioid use, and should be added to H.R and S Otherwise patients of NDs will be denied access to this life-saving treatment option, at a time of crisis when we need all available providers to practice to the full extent of their scope and education. LEGISLATIVE ASK: Fill the addiction treatment gap by leveling the playing field for patients of naturopathic doctors to be able to access the same Medication-Assisted Treatment options as other providers by amending Section 303 of CARA 2.0 to include NDs. HOUSE: Co-sponsor H.R Request a legislative hearing for H.R Energy & Commerce Committee members, especially members of the Health Subcommittee, offer an amendment to H.R to include Naturopathic Doctors to the list of providers eligible to prescribe Medication-Assisted Treatments SENATE: Co-sponsor S Request a legislative hearing for S Health, Education, Labor and Pension Committee members offer an amendment to S to include Naturopathic Doctors to the list of providers eligible to prescribe Medication-Assisted Treatments
7 American Association of Naturopathic Physicians Naturopathic Doctors and Pain Relief Chronic and acute pain is one of the most common complaints seen in medical practice. Ineffective pain control and relief has led to billions of dollars in lost productivity, including missed days from work. As a consequence of pain, there has been a galloping increase in the prescription use of opioid pain relievers, leading to unintended consequences, such as increased addiction and drug abuse. Licensed Naturopathic Doctors use a variety of safe and effective therapies to relieve pain, which - in head to head studies - show at the least a similar pain relief, with an increase of quality of life, diminished costs, fewer missed work days, and the best, no addiction to prescription medications. Some of the studies include: 1. In one trial, naturopathic therapies were estimated to save nearly $1,000 per patient with low back pain. Importantly, missed work due to illness diminished by 6.7 days, leading to return on investment of 7.9%. (Herman PM, Szczurko O, Cooley K, Mills EJ. Cost-effectiveness of naturopathic care for chronic low back pain. (2008) Altern Ther Health Med Mar-Apr 14 (2):32-39.) 2. In a complementary and alternative medicine pain clinic, Naturopathic Doctors achieved a 60% pain reduction. (Secor ER, Markow MJ, Mackenzie J, Thrall RS. Implementation of outcome measures in a complementary and alternative medicine clinic: evidence of decreased pain and improved quality of life. (2004) J Altern Complement Med 10: ) 3. In a randomized controlled trial (RCT) study on rotator cuff tendinitis in postal workers, therapies administered by Naturopathic Doctors decreased pain by over 54 percent, better than other arms in the trial, and diminished disabilities. (Szczurko O, Cooley K, Mills EJ, Zhou Q, Perri D. Naturopathic treatment of rotator cuff tendinitis among Canadian postal workers: a randomized controlled trial. (2009) Arthritis Rheum 61: ) 4. In another RCT, naturopathic therapies were compared to standard therapies for low back pain and were found to significantly benefit patients, both in decreasing pain and increasing range of motion, and were at the very least comparable to standard therapies, yet without the use of prescription medications. Quality of life improved significantly. (Szczurko O, Cooley K, Busse JW, Seely D, Bernhardt B. Naturopathic care for chronic low back pain: a randomized trial. (2007) PLoS One 2: e919) 5. In a pilot clinical trial at an HMO, Naturopathic Doctors showed significant decrease in temporomandibular jaw pain as compared to standard care. (Ritenbaugh C, Hammerschlag R, Calabrese C, Mist S, Aickin M. A pilot whole systems clinical trial of traditional Chinese medicine and naturopathic medicine for the treatment of temporomandibular disorders. (2008) J Altern Complement Med 14: ) An example of this approach is found at Southwest College of Naturopathic Medicine, where the Pain Relief Center is housed and uses a collaborative interdisciplinary approach of Naturopathic Doctors, medical doctors, and acupuncturists. Contact: Paul Mittman, ND, EdD; President/CEO Southwest College of Naturopathic Medicine, p.mittman@scnm.edu th St. NW, Suite 250, Washington, DC (202)
8
9 [Excerpt] Request to amend by adding naturopathic physician after physician assistant.
10 [Excerpt] Request to amend by adding naturopathic physician after physician assistant.
Guidance for Industry DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry DRAFT GUIDANCE This guidance
More informationCompare Results. 153 Replacements 26 Insertions 344 Deletions. Total Changes. Styling and. Content. 0 Annotations. Old File: New File:
3/1/2019 4:12:31 PM Compare Results Old File: Draft Guidance.pdf 20 pages (438 KB) 3/21/2018 3:55:17 PM versus New File: Final Guidance.pdf 21 pages (323 KB) 2/28/2019 11:42:05 AM Total Changes 523 Text
More informationPrescription Medication Guidelines for Medical Providers in CorVel s CorCare and Care IQ Networks
Prescription Medication Guidelines for Medical Providers in CorVel s CorCare and Care IQ Networks Patient Health and Safety Guidelines Prescription Medications Policy Update / April 2017 In connection
More informationSTATE & FEDERAL EFFORTS TO COMBAT THE OPIOID EPIDEMIC & IMPACT ON COMPLIANCE PROGRAMS GRACE E. REBLING OSBORN MALEDON P.A.
STATE & FEDERAL EFFORTS TO COMBAT THE OPIOID EPIDEMIC & IMPACT ON COMPLIANCE PROGRAMS GRACE E. REBLING OSBORN MALEDON P.A. Arizona Corporate Counsel Presentation May 8, 2018 Agenda 1. Overview of the Opioid
More informationStonegate Pharmacy LP 11/10/16
Stonegate Pharmacy LP 11/10/16 November 10, 2016 2017 DAL WL 03 WARNING LETTER UPS Overnight Rene F. Garza, Pharm.D., Chief Executive Officer Stonegate Pharmacy, LP 2501 W. William Cannon Drive, Suite
More informationStatement Of. The National Association of Chain Drug Stores. For. United States Senate Caucus on International Narcotics Control.
Statement Of The National Association of Chain Drug Stores For United States Senate Caucus on International Narcotics Control Hearing on: Improving Management 10:00 a.m. 226 Dirksen Senate Office Building
More informationTSDR Pharmacy Inc. dba brandmd Skin Care 11/9/17
TSDR Pharmacy Inc. dba brandmd Skin Care 11/9/17 Division of Pharmaceutical Quality Operations IV 19701 Fairchild, Irvine, CA 92612-2506 Telephone: 949-608-2900 Fax: 949-608-4417 WARNING LETTER VIA SIGNATURE
More informationWHITE PAPER ACCESS TO GOOD QUALITY DIETARY SUPPLEMENTS
WHITE PAPER ACCESS TO GOOD QUALITY DIETARY SUPPLEMENTS SEPTEMBER 23, 2009 COUNCIL OF THE CONVENTION SECTION ON THE QUALITY OF FOOD INGREDIENTS AND DIETARY SUPPLEMENTS INTRODUCTION The 1994 Dietary Supplement
More informationHieber's Pharmacy 12/5/17
Hieber's Pharmacy 12/5/17 Division of Pharmaceutical Quality Operations I 10 Waterview Blvd, 3rd FL Parsippany, NJ 07054 Telephone: (973) 331-4900 FAX: (973) 331-4969 CERTIFIED MAIL RETURN RECEIPT REQUESTED
More information10/10/2017. Disclosure
Disclosure Ronna Hauser, Vice President, Pharmacy Affairs, NCPA declares no conflicts of interest or financial interest in any product or service mentioned in this program, including grants, employment,
More informationMichigan Legislative and Regulatory Pharmacy Initiatives Update
Michigan Legislative and Regulatory Pharmacy Initiatives Update Michigan Association of Health Plans Summer Conference Carrie Germain, R.Ph. Health Alliance Plan Senior Director, Pharmacy, Quality and
More informationTown and Country Compounding and Consultation Services, LLC 10/17/17
Town and Country Compounding and Consultation Services, LLC 10/17/17 Division of Pharmaceutical Quality Operations I 10 Waterview Blvd, 3rd FL Parsippany, NJ 07054 Telephone: (973) 331-4900 FAX: (973)
More informationHistory Note: Authority G.S ; ; ; Eff. May 1, 1997; Amended Eff. January 1, 2015; March 1, 2013.
21 NCAC 46.1412 PHYSICAL REQUIREMENTS A health care facility pharmacy shall have sufficient floor space allocated to it to ensure that drugs are prepared in sanitary, well lighted, and enclosed places.
More informationHouse Committee on Energy and Commerce House Committee on Energy and Commerce. Washington, DC Washington, DC 20515
February 28, 2018 The Honorable Michael Burgess, M.D. The Honorable Gene Green Chairman Ranking Member Subcommittee on Health Subcommittee on Health House Committee on Energy and Commerce House Committee
More informationDo you CARA? A Deep Dive Into the Comprehensive Addiction and Recovery Act Joel White, President
Do you CARA? A Deep Dive Into the Comprehensive Addiction and Recovery Act Joel White, President AGENDA 01 03 05 07 By The Numbers PDMPs in CARA Action Since Enactment Questions? 02 CARA Basics 04 What
More informationTalon Compounding Pharmacy 10/3/17
Talon Compounding Pharmacy 10/3/17 Office of Pharmaceutical Quality Operations, Division II 4040 N. Central Expressway, Suite 300 Dallas, Texas 75204 October 3, 2017 CMS Case # 522630 VIA UPS EXPRESS WARNING
More informationNew Mexico. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile New Mexico Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More information2018 Farm Bill to Lift Federal Prohibition on Hemp Production, but State Laws May Restrict Certain Activities
Debevoise Update D&P 2018 Farm Bill to Lift Federal Prohibition on Hemp Production, but State Laws May Restrict Certain Activities December 13, 2018 Earlier this week, the U.S. House of Representatives
More informationReview of Controlled Drugs and Substances Act
Review of Controlled Drugs and Substances Act Canadian Medical Association: Submission to Health Canada in response to the consultation on the Controlled Drugs and Substances Act and its regulations A
More informationThe Changing Landscape of Opioids & Workers Compensation. Presented by: David Campbell, MA, CRC State of Michigan Workers Compensation Agency
The Changing Landscape of Opioids & Workers Compensation Presented by: David Campbell, MA, CRC State of Michigan Workers Compensation Agency 1 The Changing Landscape of Opioids & Workers Compensation is
More informationSan Diego Compounding Pharmacy 9/25/17
San Diego Compounding Pharmacy 9/25/17 Division of Pharmaceutical Quality Operations IV 19701 Fairchild Road Los Angeles, CA 92612 WARNING LETTER VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED September
More informationStatement of the National Community Pharmacists Association (NCPA)
Statement of the National Community Pharmacists Association (NCPA) United States House Committee on Energy and Commerce Oversight and Investigations Subcommittee Hearing on The Fungal Meningitis Outbreak:
More informationUS H.R.6 of the 115 th Congress of the United States Session
US H.R.6 of the 115 th Congress of the United States 2017-2018 Session This Act may be cited as the Substance Use Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities
More informationOne Hundred Ninth Congress of the United States of America
S. 843 One Hundred Ninth Congress of the United States of America AT THE SECOND SESSION Begun and held at the City of Washington on Tuesday, the third day of January, two thousand and six An Act To amend
More informationSENATE, No STATE OF NEW JERSEY. 218th LEGISLATURE INTRODUCED FEBRUARY 5, 2018
SENATE, No. STATE OF NEW JERSEY th LEGISLATURE INTRODUCED FEBRUARY, 0 Sponsored by: Senator JEFF VAN DREW District (Atlantic, Cape May and Cumberland) SYNOPSIS Compounding Pharmacy Quality Assurance Act
More informationperpetuate -- and perhaps even intensify -- that controversy. 1 On July 18th, the Fifth Circuit affirmed FDA s longstanding position that
Food & Drug July 29, 2008 Fifth Circuit Rules that FDA May Regulate Compounded Drugs as New Drugs Update on Medical Center Pharmacy v. Mukasey For decades, the pharmacy compounding industry has disputed
More informationSeptember 1, The Honorable Tom Price, MD Secretary Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201
September 1, 2017 The Honorable Tom Price, MD Secretary Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201 Dear Secretary Price: The National Association of County
More informationCARD/MAIL/PRE-APPROVAL/PREFERRED RIDER FOR PRESCRIPTION DRUG [INSURANCE] [Policy]holder: Group Policy No: Effective Date:
RIDER FOR PRESCRIPTION DRUG [INSURANCE] [Policy]holder: Group Policy No: Effective Date: CARD/MAIL/PRE-APPROVAL/PREFERRED The Prescription Drug Coverage under this Rider [replaces] [supplements] the Prescription
More informationLEGISLATIVE UPDATE OPIOID CRISIS IMPACT OF GLOBAL, FEDERAL, AND STATE INITIATIVES
LEGISLATIVE UPDATE OPIOID CRISIS IMPACT OF GLOBAL, FEDERAL, AND STATE INITIATIVES TPF 10 TH Annual Scientific Meeting 11.4.2018 CM SCHADE, MD, PHD, PE, FIPP Advanced Pain Solutions Past President Texas
More informationWEAMA November 2017 Legislative Update
Legislative Overview Prepared by Leslie Emerick, Lobbyist November 8, 2017 The election was held on November 7th and it is now determined that the Senate will be controlled by the Democrats in 2018 because
More informationISSUING AGENCY: Regulation and Licensing Department - NM Board of Osteopathic Medical Examiners.
Code of New Mexico Rules Title 16. Occupational and Professional Licensing Chapter 17. Osteopathic Medicine and Surgery Practitioners Part 5. Prescribing and Distribution of Controlled Substances 16.17.5.
More informationOCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES
TITLE 16 CHAPTER 10 PART 14 OCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES 16.10.14.1 ISSUING AGENCY: New
More informationStatement Of. The National Association of Chain Drug Stores. For. U.S. Senate Finance Committee. Hearing on:
Statement Of The National Association of Chain Drug Stores For U.S. Senate Finance Committee Hearing on: 10:30 a.m. 215 Dirksen Senate Office Building National Association of Chain Drug Stores (NACDS)
More informationAppendix F Federation of State Medical Boards
Appendix F Federation of State Medical Boards Model Policy Guidelines for Opioid Addiction Treatment in the Medical Office SECTION I: PREAMBLE The (name of board) recognizes that the prevalence of addiction
More information720 cases. 20 states. Conflict of Interest Declaration. New England Compounding Center (NECC) timeline. (NECC) timeline (continued) 3/28/2013
Conflict of Interest Declaration Compounding at a Crossroads: The Federal and State Outlook Christopher J. Topoleski has no actual or potential conflicts of interest in relation to this activity Christopher
More informationPublic Policy Statement on the Regulation of Office-Based Opioid Treatment
Public Policy Statement on the Regulation of Office-Based Opioid Treatment Background Office-based opioid treatment (OBOT) commonly refers to outpatient treatment services provided outside of licensed
More informationIOWA COALITION ON MENTAL HEALTH AND AGING. Policy and Administration Workgroup
IOWA COALITION ON MENTAL HEALTH AND AGING Policy and Administration Workgroup PRIMARY GOALS Make mental wellness a priority issue for policy makers Make mental wellness a priority among program administrators
More informationSubmitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis
STATEMENT FOR THE RECORD Submitted to the House Energy and Commerce Committee Federal Efforts to Combat the Opioid Crisis October 25, 2017 America s Health Insurance Plans 601 Pennsylvania Avenue, NW Suite
More informationDispensing and administration of emergency opioid antagonist without a
68-7-23. Dispensing and administration of emergency opioid antagonist without a prescription. (a) A pharmacist may dispense an FDA-approved emergency opioid antagonist and the necessary medical supplies
More informationArizona s Oral Anticancer Treatment Access Law: What Clinicians Need to Know
Outdated coverage policies in Arizona USED TO limit cancer patients access to lifesaving drugs! Traditionally, IV chemotherapy treatments are covered under a health plan s medical benefit where the patient
More informationRULES OF THE TENNESSEE BOARD OF PHARMACY CHAPTER DRUG DONATION REPOSITORY PROGRAM TABLE OF CONTENTS
RULES OF THE TENNESSEE BOARD OF PHARMACY CHAPTER 1140-17 DRUG DONATION REPOSITORY PROGRAM TABLE OF CONTENTS 1140-17-.01 Definitions 1140-17-.02 Purpose 1140-17-.03 Eligibility Criteria for Program Participation
More informationA Bill Regular Session, 2015 SENATE BILL 717
Stricken language would be deleted from and underlined language would be added to present law. 0 State of Arkansas 0th General Assembly As Engrossed: S// H// A Bill Regular Session, SENATE BILL By: Senator
More informationSANTA BARBARA COUNTY DEPARTMENT OF Behavioral Wellness A System of Care and Recovery
Page 1 of 9 SANTA BARBARA COUNTY DEPARTMENT OF Behavioral Wellness A System of Care and Recovery Departmental Polley and Procedure Section Sub-section Alcohol and Drug Program (ADP) Effective: 7/11/2018
More informationWednesday, June 21, Dear Chairmen and Ranking Members:
The Honorable Rodney Frelinghuysen Committee on Appropriations 2306 Rayburn House Office Building The Honorable Tom Cole Subcommittee on Labor, Health and Human Services, Education and Related Agencies
More informationREGULATORY IMPACT STATEMENT and COST-BENEFIT ANALYSIS (RISCBA)
State Budget Office Office of Regulatory Reinvention 111 S. Capitol Avenue; 8th Floor, Romney Building Lansing, MI 48933 Phone: (517) 335-8658 FAX: (517) 335-9512 REGULATORY IMPACT STATEMENT and COST-BENEFIT
More informationPage 1 of 5 Source: Health IT Law & Industry Report: News Archive > 2018 > 0 > Bloomberg Law Insights > Understanding the Implications of Federal Remote Prescribing Laws on Telemedicine's Role in Behavioral
More information16 SB 319/AP. Senate Bill 319 By: Senators Jackson of the 2nd, Kirk of the 13th, Unterman of the 45th, Henson of the 41st and Orrock of the 36 th
1 2 3 4 5 6 7 8 9 10 11 12 13 Senate Bill 319 By: Senators Jackson of the 2nd, Kirk of the 13th, Unterman of the 45th, Henson of the 41st and Orrock of the 36 th AS PASSED A BILL TO BE ENTITLED AN ACT
More informationLegislative and Regulatory Update Michael Baxter APhA Director, Regulatory Affairs
Legislative and Regulatory Update 2018 Michael Baxter APhA Director, Regulatory Affairs 1 CPE Information and Disclosures Michael Baxter declares no conflicts of interest, real or apparent, and no financial
More informationImplementation: Public Hearing: Request for Comments (FDA-2017-N-6502)
March 16, 2018 via online submission: www.regulations.gov The Honorable Scott Gottlieb Commissioner Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Re: Opioid Policy Steering
More informationPrepublication Requirements
Issued Prepublication Requirements The Joint Commission has approved the following revisions for prepublication. While revised requirements are published in the semiannual updates to the print manuals
More informationChairwoman Bono Mack, Vice-Chairwoman Blackburn, Ranking Member Butterfield and
United States House of Representatives Committee on Energy and Commerce Subcommittee on Commerce, Manufacturing and Trade Hearing on Chairwoman Bono Mack, Vice-Chairwoman Blackburn, Ranking Member Butterfield
More informationUSP <797> Overview and Compliance Audit Results. Joseph W. Coyne RPh Director of Field Operations Clinical IQ, LLC
USP Overview and Compliance Audit Results Joseph W. Coyne RPh Director of Field Operations Clinical IQ, LLC Acknowledgements Many of the slides presented in this program come from the CriticalPoint
More informationCoventry Health Care of Georgia, Inc.
Coventry Health Care of Georgia, Inc. PRESCRIPTION DRUG RIDER (for High Deductible Health Plans) This Prescription Drug Rider is an attachment to the Coventry Health Care of Georgia, Inc. ( Health Plan
More informationSTATEMENT. of the. American Medical Association. for the Record. House Committee on Energy and Commerce
STATEMENT of the American Medical Association for the Record House Committee on Energy and Commerce RE: Federal Efforts to Combat the Opioid Crisis: A Status Update on CARA and Other Initiatives October
More information1 HB By Representative Williams (JD) 4 RFD: Health. 5 First Read: 09-JAN-18 6 PFD: 11/28/2017. Page 0
1 HB37 2 188862-1 3 By Representative Williams (JD) 4 RFD: Health 5 First Read: 09-JAN-18 6 PFD: 11/28/2017 Page 0 1 188862-1:n:11/16/2017:PMG/tj LSA2017-3516 2 3 4 5 6 7 8 SYNOPSIS: This bill would establish
More informationH 7816 S T A T E O F R H O D E I S L A N D
LC00 01 -- H 1 S T A T E O F R H O D E I S L A N D IN GENERAL ASSEMBLY JANUARY SESSION, A.D. 01 A N A C T RELATING TO BUSINESSES AND PROFESSIONS - PHARMACIES Introduced By: Representatives Serpa, Canario,
More informationBoard of Pharmacy Update
Board of Pharmacy Update Gay Dodson, R.Ph. Executive Director/Secretary Texas Pain Society s 6 th Annual Scientific Meeting October 26, 2014 Goals Review some recent changes to federal law. Review some
More informationPursuant to the authority vested in the Commissioner of Health by section 3369-a of the Public
Medical Use of Marihuana Effective date: 7/12/18 Pursuant to the authority vested in the Commissioner of Health by section 3369-a of the Public Health Law (PHL), Section 1004.2 of Title 10 (Health) of
More informationPerformance of North Carolina's System for Monitoring Prescription Drug Abuse. Session Law , Section 12F.16.(q)
Performance of North Carolina's System for Monitoring Prescription Drug Abuse Session Law 2015-241, Section 12F.16.(q) Report to the Joint Legislative Oversight Committee on Health and Human Services and
More informationSub. S.B. 119 As Passed by the Senate
AM3404 Sub. S.B. 119 As Passed by the Senate Topic: Opioid Data and Communication Expansion Act moved to amend as follows: In line 1 of the title, after "4723.52," insert "4729.01, 4729.44, 4729.75, 4729.79,
More informationSENATE, No STATE OF NEW JERSEY. 217th LEGISLATURE INTRODUCED FEBRUARY 8, 2016
SENATE, No. STATE OF NEW JERSEY th LEGISLATURE INTRODUCED FEBRUARY, 0 Sponsored by: Senator JOSEPH F. VITALE District (Middlesex) SYNOPSIS Makes it a crime of the third degree to practice psychology without
More information4/26/2018. Bureau of Professional Licensing. MAPS Updates & Opportunities. MAPS Background. Registration. MAPS Update
Bureau of Professional Licensing MAPS Updates & Opportunities April 28, 2018 Presented by Andrew Hudson, Manager Haley Winans, Analyst Drug Monitoring Section Bureau of Professional Licensing BPL-MAPS@Michigan.gov
More informationAmerican Academy of Pain Medicine American Pain Society American Society of Anesthesiologists
PAIN CARE COALITION A National Coalition for Responsible Pain Care American Academy of Pain Medicine American Pain Society American Society of Anesthesiologists August 29, 2017 The Honorable Chris Christie,
More information51ST LEGISLATURE - STATE OF NEW MEXICO - FIRST SESSION, 2013
SENATE BILL ST LEGISLATURE - STATE OF NEW MEXICO - FIRST SESSION, 0 INTRODUCED BY Peter Wirth 0 AN ACT RELATING TO COMMERCE; AMENDING AND ENACTING SECTIONS OF THE NEW MEXICO FOOD ACT AND THE COMMERCIAL
More informationThe FDA Food Safety Modernization Act: The Key New Requirements
June 15, 2011 The FDA Food Safety Modernization Act: The Key New Requirements Executive Summary INSTITUTE FOR FOOD LAWS & REGULATIONS Michigan State University 140 G.M. Trout Building East Lansing, MI
More informationThe Challenge of Treating Pain
FDA Charge to the Committee: FDA Opioid Action Plan and Incorporating the Broader Public Health Impact into the Formal Risk-Benefit Assessment for Opioids Robert M. Califf, MD Commissioner of Food and
More informationDear DEA. Howard A. Heit, MD, FACP, FASAM,* Edward Covington, MD, and Patricia M. Good
PAIN MEDICINE Volume 5 Number 3 2004,* Edward Covington, MD, and Patricia M. Good *Georgetown University, Washington, District of Columbia; Cleveland Clinic Foundation, Cleveland, Ohio; Office of Diversion
More informationprototypes from the myriad conventional drug classes. In addition, the ND must thoroughly understand the pharmacology of all natural substances.
For many decades, BC s naturopathic physicians have been seeking from government recognition for a scope of practice in keeping with the contemporary and historical practice of NDs. In the 2008 Throne
More informationRole of PMPs in Preventing Substance Abuse National Conference of State Legislatures December 6, 2006 San Antonio, Tx
Role of PMPs in Preventing Substance Abuse National Conference of State Legislatures December 6, 2006 San Antonio, Tx Nick Reuter Division of Pharmacologic Therapy Substance Abuse and Mental Health Services
More informationWhich was the greatest problem with patent medicines in early America that lead to drug legislation?
Pharmacology Connections to Nursing Practice 3rd Edition Adams Test Bank Full Download: http://testbanklive.com/download/pharmacology-connections-to-nursing-practice-3rd-edition-adams-test-bank/ Adams
More informationFDA Oversight of Nanotechnology Applications in Foods, Food Packaging, and Nutrient Delivery
FDA Oversight of Nanotechnology Applications in Foods, Food Packaging, and Nutrient Delivery Laura M. Tarantino, Ph.D. Office of Food Additive Safety Center for Food Safety and Applied Nutrition (CFSAN)
More informationHEB Pharmacy Conference October 25, 2014
Texas State Board of Pharmacy Laws and Rules Update Allison Benz, R.Ph., M.S. Director of Professional Services Central Texas Society of Health-System Pharmacists Annual Seminar October 25, 2014 Texas
More informationNCPA LTC Division Newsletter
March 2016 NCPA LTC Division Newsletter NCPA Offers FDA Additional Information on Repackaging Draft Guidance NCPA recently joined with the American Society of Consultant Pharmacists (ASCP) in a follow
More informationDo not open the test booklet prior to being told to do so.
Last Name: Pharmacy 4054 Pharmacy Law Exam II Do not open the test booklet prior to being told to do so. I, the undersigned student, agree to do my best on the exam and that I have only used resources
More informationASSEMBLY, No STATE OF NEW JERSEY. 216th LEGISLATURE INTRODUCED MAY 15, 2014
ASSEMBLY, No. STATE OF NEW JERSEY th LEGISLATURE INTRODUCED MAY, 0 Sponsored by: Assemblyman RONALD S. DANCER District (Burlington, Middlesex, Monmouth and Ocean) Assemblyman HERB CONAWAY, JR. District
More informationAACE LEGISLATIVE FACT SHEET
AACE LEGISLATIVE FACT SHEET INCREASING ACCESS TO OSTEOPOROSIS TESTING FOR MEDICARE BENEFICIARIES ACT (H.R. 1898/S. 3160) REQUEST: Please co-sponsor this legislation that provides a sustainable Medicare
More informationSubtitle E--National Bioengineered Food Disclosure Standard
GMO Labeling Bill S.764 as of July 14, 2016* [Congressional Bills 114th Congress] [From the U.S. Government Publishing Office]* [S. 764 Enrolled Bill (ENR)] S.764 One Hundred Fourteenth Congress of the
More informationS 2356 SUBSTITUTE A AS AMENDED ======== LC004564/SUB A/3 ======== S T A T E O F R H O D E I S L A N D
0 -- S SUBSTITUTE A AS AMENDED LC00/SUB A/ S T A T E O F R H O D E I S L A N D IN GENERAL ASSEMBLY JANUARY SESSION, A.D. 0 A N A C T RELATING TO HEALTH AND SAFETY -- INSURANCE--MENTAL ILLNESS AND SUBSTANCE
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 6 Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations A Nelson & Co.,
More informationPandemic Influenza: Appropriations for Public Health Preparedness and Response
Order Code RS22576 January 23, 2007 Pandemic Influenza: Appropriations for Public Health Preparedness and Response Summary Sarah A. Lister Specialist in Public Health and Epidemiology Domestic Social Policy
More informationGENERAL ASSEMBLY OF NORTH CAROLINA SESSION HOUSE BILL DRH20012-MGfa-35H* (01/26)
H GENERAL ASSEMBLY OF NORTH CAROLINA SESSION HOUSE BILL DRH0-MGfa-H* (01/) H.B. Mar, HOUSE PRINCIPAL CLERK D Short Title: Strengthen Opioid Misuse Prevention (STOP)Act. (Public) Sponsors: Referred to:
More informationProposed Amendment of 10A NCAC 26E.0603 Requirements for Transmission of Data
Proposed Amendment of 10A NCAC 26E.0603 Requirements for Transmission of Data Agency: Contact: DHHS/ Mental Health, Developmental Disabilities, and Substance Abuse Services Amanda Reeder, Rule-Making Coordinator
More informationGOVERNMENT S ROLE IN ADDRESSING PRESCRIPTION DRUG ABUSE
POSITION PAPER GOVERNMENT S ROLE IN ADDRESSING PRESCRIPTION DRUG ABUSE Governments across Canada are concerned about the abuse of prescription drugs, with recent policy discussions focused on mitigating
More informationTitle of Session: Restricting the Marketing and Advertising of Opioids in Canada Date of Session: September 5, 2018
Title of Session: Restricting the Marketing and Advertising of Opioids in Canada Date of Session: September 5, 2018 Purpose To update stakeholders on Health Canada s actions to date, and to consult on
More informationRE: Permits under the Arizona Pharmacy Act should not be required for dietary supplements
Board Members Arizona State Board of Pharmacy 1616 W. Adams St., Suite 120 Phoenix, AZ 85007 c/o Kam Gandhi, PharmD Executive Director Arizona State Board of Pharmacy Via email: kgandhi@azpharmacy.gov
More information[First Reprint] ASSEMBLY, No STATE OF NEW JERSEY. 217th LEGISLATURE INTRODUCED FEBRUARY 4, 2016
[First Reprint] ASSEMBLY, No. STATE OF NEW JERSEY th LEGISLATURE INTRODUCED FEBRUARY, 0 Sponsored by: Assemblyman DANIEL R. BENSON District (Mercer and Middlesex) Assemblywoman VALERIE VAINIERI HUTTLE
More informationGAO. PRESCRIPTION DRUGS State and Federal Oversight of Drug Compounding by Pharmacies
GAO For Release on Delivery Expected at 10:00 a.m. Thursday, October 23, 2003 United States General Accounting Office Testimony Before the Committee on Health, Education, Labor, and Pensions, U.S. Senate
More informationHealth Care Bills Introduced in Congress April 16 to April 20, 2018
Date Bill Number House/Senate Sponsors Bill Title Committee of Jurisdiction HOUSE 4/17 H.R.5531 4/17 H.R.5541 Rep. Buchanan (R-FL) Rep. Upton (R-MI) To provide for a comprehensive, multifaceted approach
More informationAddressing the Opioid Crisis Policy Recommendations
Addressing the Opioid Crisis Policy Recommendations The Pew Charitable Trusts Pew is an independent nonprofit, nonpartisan research and policy organization. Tools: Research Partnerships Technical assistance
More informationFundamentals of Pharmacology for Veterinary Technicians Chapter 1
1906 1914 1933 1937 1938 1941 1951 1965 1968 1970 1970 1972 1972 1983 1984 1988 1994 1994 1996 1997 2001 2003 2008 The original Pure Food and Drug Act is passed by Congress on June 30 and signed by President
More informationThe SUPPORT for Patients and Communities Act (P.L ): Medicare Provisions
The SUPPORT for Patients and Communities Act (P.L.115-271): Medicare s Updated January 2, 2019 Congressional Research Service https://crsreports.congress.gov R45449 SUMMARY The SUPPORT for Patients and
More informationNOTICE OF INTENT. Department of Health and Hospitals Board of Dentistry
NOTICE OF INTENT Department of Health and Hospitals Board of Dentistry Fees and Costs; Anesthesia/Analgesia Administration; Continuing Education Requirements (LAC 46:XXXIII.134,.306,.706,.1505,.1607,.1611,.1613,.1709,
More informationFamily Smoking Prevention and Tobacco Control Act. Comments regarding crop protection agents
Family Smoking Prevention and Tobacco Control Act (PUBLIC LAW 111-31 JUNE 22, 2009) Comments regarding crop protection agents Presentation Objectives What is the intent of FDA in regulating CPAs? What
More informationCHAPTER Section 1 of P.L.1999, c.105 (C.30:6D-56) is amended to read as follows:
CHAPTER 168 AN ACT concerning medical research and treatment of autism, amending and supplementing P.L.1999, c.105 and amending P.L.2001, c.338 and P.L.2003, c.144. BE IT ENACTED by the Senate and General
More informationThe Ryan White Comprehensive AIDS Resources Emergency (CARE) Act: A Side-by-Side Comparison of Current Law and Reauthorization Proposals
The Ryan White Comprehensive AIDS Resources Emergency (CARE) Act: A Side-by-Side Comparison of Current Law and Reauthorization Proposals june 2006 Jennifer Kates Kaiser Family Foundation The Ryan White
More informationDRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT
c t DRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT PLEASE NOTE This document, prepared by the Legislative Counsel Office, is an office consolidation of this Act, current to September 22, 2014. It is intended
More information3 By Representatives Sells, Weaver, Harper, South, McCutcheon, 4 Harbison, Butler, Mooney, Hanes, Williams (JW), Wilcox, Scott,
1 HB379 2 175235-1 3 By Representatives Sells, Weaver, Harper, South, McCutcheon, 4 Harbison, Butler, Mooney, Hanes, Williams (JW), Wilcox, Scott, 5 Givan, Rogers, Moore (M), Ingram, Polizos, Baker and
More informationPHARMACY 543 PHARMACY LAWS & ETHICS MIDTERM EXAMINATION October 29, 1998
PHARMACY 543 PHARMACY LAWS & ETHICS MIDTERM EXAMINATION October 29, 1998 Questions 1 20 are multiple choice; please record answers on Side 2 of a Standard Answer Sheet, Form 1158. Follow the instructions
More information